TITAN PHARMACEUTICALS INC (TTNP) Stock Price & Overview

NASDAQ:TTNP • US8883147055

Current stock price

4.61 USD
-0.18 (-3.76%)
At close:
5.91 USD
+1.3 (+28.2%)
After Hours:

The current stock price of TTNP is 4.61 USD. Today TTNP is down by -3.76%. In the past month the price increased by 9.76%. In the past year, price decreased by -13.02%.

TTNP Key Statistics

52-Week Range3.03 - 5.76
Current TTNP stock price positioned within its 52-week range.
1-Month Range3.84 - 4.8001
Current TTNP stock price positioned within its 1-month range.
Market Cap
6.131M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-5.23
Dividend Yield
N/A

TTNP Stock Performance

Today
-3.76%
1 Week
+7.63%
1 Month
+9.76%
3 Months
+4.77%
Longer-term
6 Months +25.93%
1 Year -13.02%
2 Years -42.45%
3 Years -76.95%
5 Years -94.52%
10 Years -99.97%

TTNP Stock Chart

TITAN PHARMACEUTICALS INC / TTNP Daily stock chart

TTNP Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to TTNP. When comparing the yearly performance of all stocks, TTNP is a bad performer in the overall market: 69.92% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

TTNP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TTNP. TTNP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TTNP Earnings

Next Earnings DateJan 1, 2026
Last Earnings DateAug 13, 2025
PeriodQ4 / 2024
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

TTNP Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

TTNP Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

TTNP Financial Highlights

Over the last trailing twelve months TTNP reported a non-GAAP Earnings per Share(EPS) of -5.23. The EPS increased by 29.34% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-4.71M
Industry RankSector Rank
PM (TTM) N/A
ROA -161%
ROE -192.87%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%66.89%
Sales Q2Q%N/A
EPS 1Y (TTM)29.34%
Revenue 1Y (TTM)-100%

TTNP Ownership

Ownership
Inst Owners3.56%
Shares1.33M
Float670.00K
Ins Owners29.69%
Short Float %N/A
Short RatioN/A

About TTNP

Company Profile

TTNP logo image Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. The company is headquartered in San Francisco, California. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.

Company Info

IPO: 1996-01-18

TITAN PHARMACEUTICALS INC

Suite 505, 400 Oyster Point Blvd

San Francisco CALIFORNIA 94080 US

CEO: Marc Rubin

Employees: 4

TTNP Company Website

TTNP Investor Relations

Phone: 14152444990

TITAN PHARMACEUTICALS INC / TTNP FAQ

What does TTNP do?

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. The company is headquartered in San Francisco, California. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.


Can you provide the latest stock price for TITAN PHARMACEUTICALS INC?

The current stock price of TTNP is 4.61 USD. The price decreased by -3.76% in the last trading session.


What is the dividend status of TITAN PHARMACEUTICALS INC?

TTNP does not pay a dividend.


What is the ChartMill rating of TITAN PHARMACEUTICALS INC stock?

TTNP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the GICS sector and industry of TTNP stock?

TITAN PHARMACEUTICALS INC (TTNP) operates in the Health Care sector and the Pharmaceuticals industry.


Would investing in TITAN PHARMACEUTICALS INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TTNP.


Can you provide the upcoming earnings date for TITAN PHARMACEUTICALS INC?

TITAN PHARMACEUTICALS INC (TTNP) will report earnings on 2026-01-01.